Table 1. BLyS receptor expression in WM... | American Society of Hematology

Table 1.

BLyS receptor expression in WM patients

Patient	Age, y	Sex	Lym	Spl	BAFF-R	BCMA	TACI
WM1	77	M	No	No	+++	+	++
WM2	50	M	No	No	+++	—	+
WM3	78	M	Yes	No	+++	++	++
WM4	83	M	Yes	No	+	—	+
WM5	62	M	No	No	++	+	+
WM16	67	M	Yes	Yes	+	++	—
WM17	88	F	No	Yes	+	+	+
WM18	81	M	Yes	No	++	+	+
WM19	75	M	No	No	++	+	+
WM20	88	F	No	No	++	—	—
WM21	67	F	No	No	++	+	++
WM22	77	F	No	No	+	—	—

Patient	Age, y	Sex	Lym	Spl	BAFF-R	BCMA	TACI
WM1	77	M	No	No	+++	+	++
WM2	50	M	No	No	+++	—	+
WM3	78	M	Yes	No	+++	++	++
WM4	83	M	Yes	No	+	—	+
WM5	62	M	No	No	++	+	+
WM16	67	M	Yes	Yes	+	++	—
WM17	88	F	No	Yes	+	+	+
WM18	81	M	Yes	No	++	+	+
WM19	75	M	No	No	++	+	+
WM20	88	F	No	No	++	—	—
WM21	67	F	No	No	++	+	++
WM22	77	F	No	No	+	—	—

In all patients, the BLyS receptor bound BLyS.

Lym indicates lymphadenopathy; Spl, splenomegaly; +++, high expression (MFI > 21); +, low expression (MFI, 2-6); ++, intermediate expression (MFI, 7-20); no expression (MFI < 2).

None of the patients used in these studies had any ongoing inflammatory infections that would increase BLyS levels.

View Large

This Feature Is Available To Subscribers Only